RCS - Diaceutics PLC - Sub-optimal testing impacts on cancer patients

DiaceuticsAnnouncement

01/11/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA8164Ea&default-theme=true

RNS Number : 8164E  Diaceutics PLC  01 November 2022

 

01 November 2022

Diaceutics PLC

("Diaceutics" or "the Company")

 

Release of study into inefficiencies within Personalised Medicine and its
impact on cancer patients

 

Ground-breaking findings show that 64% of lung cancer patients in 2019 in the
US missed getting the appropriate treatment

 

DXRX platform-enabled study highlights the need to address factors limiting
the impact of personalised medicine within the cancer diagnosis and testing
journey

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
diagnostic commercialisation company which provides data, analytics and
technology enabled services via its proprietary DXRX platform to the Precision
Medicine market, announces the release of a large-scale study highlighting
that a significant number of eligible patients treated for lung cancer did not
receive access to the medicines most suitable to them, and therefore did not
benefit from personalised medicine treatment.

 

The study, carried out in conjunction with a broad stakeholder group across
the Personalised Medicine Coalition, was made possible by the Diaceutics Data
Repository, a database consisting of 600 million patient records available on
the DXRX platform. The study examined de-identified Medicare claims and
laboratory data from 38,068 US-based patients diagnosed with advanced
non-small cell lung cancer in 2019 to identify the operational inefficiencies
in the diagnosis and testing journey across this dataset.

 

Overall, the publication identified that diagnostic testing-informed treatment
strategies benefitted only 36% of the patients in the cohort. Of this group,
18% of patients did not receive the correct treatment as a result of
inconclusive or false negative diagnostic results, and 29% of patients who had
a successful diagnostic test were not prescribed the indicated treatment that
they could have benefitted from.

 

A full list of the seven clinical practice gaps found from the study is
included further below this announcement.

 

These findings represent the first step in understanding and pinpointing the
nuances behind what prevents millions of people from getting the correct and
timely healthcare they need. While the study was collected from US-based data,
the findings are significant and reflective of the clinical gaps across other
geographies and cancer types.

 

For the pharmaceutical community, the study highlights the need for greater
investment into those technologies and data repositories which facilitate the
wider application of personalised medicines. It also provides the basis for
better understanding the action required by these stakeholders to tackle these
clinical gaps, and to track progress going forward.

 

Diaceutics' Data Repository represents a world-leading diagnostic data set,
combining multiple sources of information to build a complete picture of a
typical patient's diagnostic journey. The mining capability of the DXRX
platform allows the Company to identify Disease Diagnostic Pathways (DDPs) to
determine the best possible testing journey for patients within a specific
disease or disease area. The DDPs are both unique and proprietary to
Diaceutics and are increasingly being developed for other therapeutic areas.
As Diaceutics invests further in its platform, it will utilise access to the
unrivalled wealth of data to continue removing testing hurdles and increasing
patients' access to precision medicine.

 

The peer-reviewed study is published in JCO Precision Oncology. Further
information on the study, titled "The Impact of Clinical Practice Gaps on the
Implementation of Personalised Medicine in Advanced Non-Small Cell Lung
Cancer", can be downloaded here (https://lp.diaceutics.com/knowtestingnow/) .

 

Peter Keeling, Chief Executive Officer of Diaceutics, said:

"For the first time, through the use of large, real-world diagnostic testing
data, we are able to verify the limitations within the diagnostic and
treatment journey for the millions of cancer patients worldwide. These
inefficiencies can, in the worst cases, inhibit patient recovery and reduce
the quality of life for those who are terminally ill.

"Without the access to the highly specific data that can be generated by DXRX,
it would have been difficult to generate these findings, which are clearly a
cause for concern. Providing the specific data required for this study
confirms our commitment to broadening the routine adoption, scale and
efficiency of Personalised Medicine. The wider use of the DXRX platform itself
and the DDPs that it generates will help ensure every patient is able to
access the most appropriate treatment for their needs.

"More than ever, there is an urgent need for greater investment and a
multi-stakeholder approach across labs, healthcare professionals and policy
makers to ensure the significant benefits of personalised medicine are more
widely felt. Diaceutics' proprietary DXRX platform is ideally placed to
provide the core data to catalyse this collaborative approach."

 

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

Diaceutics' data capability is one of the three key value drivers it has
integrated into its unique DXRX platform alongside its global Lab network and
product suite tailored for Precision testing.

 

About the Personalised Medicine Coalition:

The Personalised Medicine Coalition, a 501(c)3 organisation comprised of 14
distinct stakeholder groups within health care, promotes the understanding and
adoption of Personalised Medicine concepts, services, and products to benefit
patients and the health system.

For more information, please visit www.personalizedmedicinecoalition.org
(http://www.personalizedmedicinecoalition.org) .

 

About JCO Precision Oncology

JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only journal
publishing original research, reports, opinions, and reviews that advance the
science and practice of precision oncology and define genomics and other
biomarker-driven clinical care of patients with cancer. Innovative and timely
scientific and educational content provide a deeper understanding of
actionable cancer genomics, personalised translational and clinical oncology
research, and recent treatment advances based on tumour molecular profiling.

 

 

 

The Impact of Clinical Practice Gaps on the Implementation of Personalised
Medicine in Advanced Non-Small Cell Lung Cancer:

 

Seven ways in which clinical practice gaps limit the extent to which
breakthroughs in Personalised Medicine benefit patients in clinical settings.

 

 Reason patients could not access precision medicine                             % of patients per 1,000 affected
 clinicians did not prescribe a targeted or immuno-oncology therapy the patient  29.2
 could have benefitted from
 genetic or genomic sequencing-based testing delivered inconclusive or           18.3
 false-negative results, usually for technical reasons or because of known
 testing limitations
 clinicians did not order the genetic or genomic sequencing-based testing        18.1
 necessary to uncover actionable biomarkers
 clinicians' attempts to collect the necessary tumour tissue or blood samples    14.5
 were unsuccessful
 clinicians never attempted to collect the tumour tissue or blood samples        6.6
 needed to uncover actionable biomarkers
 long turnaround times for test results prompted physicians and patients to      4
 initiate treatment regimens before testing results were available
 the collected biospecimen did not contain enough tumour cells to allow for      1.7
 testing to uncover actionable biomarkers

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMBBLTMTIJBBT